a simple vaccine can be a powerful tool in fighting climate change

ArkeaBio™ is an agricultural science company developing a vaccine targeted to reduce livestock methane that is not only safe and cost-effective, but also realistic for large-scale execution using existing agronomic practices

the problem

livestock methane emissions total over 3 billion Tonnes per year of CO2 equivalents and are responsible for 6% of GHGs

Methane is a potent greenhouse gas (GHG) that has a much greater impact on the environment compared to carbon dioxide (CO2). Over a 100-year period, methane has a global warming potential of around 28x higher than CO2, with the predominant impact occurring over the next 10 years. These methane emissions account for more GHGs than:









Reducing methane emissions from the agricultural sector, including livestock, is imperative to mitigate the effects of climate change.

The world urgently needs solutions to mitigate GHGs.

Our vaccination-based approach allows for much-needed decarbonization of global meat and dairy products across multiple geographies, supporting greater sustainability in agriculture.

Vaccines can be quickly deployed worldwide at scale, providing ArkeaBio with an unmatched opportunity to make near-term global climate impact.

our opportunity

the recent convergence of vaccine development technologies and capabilities has created a unique and rapidly executable opportunity to significantly reduce GHGs

our solution

an anti-methanogen vaccine provides a singular technical solution for a distributed worldwide problem

Our vaccine solution will be safe, additive free, cost-effective, rapidly deployable and integrable at scale via existing agronomic practices.

our continuous
development cycle
defining targets in the rumen microbiome
target refinement
vaccine formulation
immune response creates antibodies
antibodies neutralize methanogens
methanogen population is reduced
reduced rumen methane production
animal measurements
our continuous
development cycle
our ArkeaBio

our team is built on the foundation of strong scientific and commercial leaders

Colin South is a leader in the field of agricultural biotech. Coming from a farming background in New Zealand, he has over 25 years’ experience as a leader developing high value bioproducts with direct applicability to food, feed, and energy industries. Colin holds a degree in chemical engineering from University of Canterbury, as well as a Master’s degree in engineering management and a PhD in bioprocess engineering from Dartmouth College.
Colin South

Matt Dunn has extensive experience in biochemistry and molecular biology, in particular nucleic acid protein engineering and evolution, to develop commercially relevant bioproducts. He leverages computational biology and high throughput screening strategies to accelerate the identification of biomolecules of interest, directly facilitating ArkeaBio’s vaccine development efforts. Matt is also versed in the development of comprehensive IP strategies for early-stage companies, including filing and prosecuting key patent applications for core technology. Matt holds a degree in genetics, cell, and developmental biology from UC Irvine and a PhD in molecular and cellular biology from Arizona State University.

Matt Rock Climbing

Kristin Adolfsen is a microbiologist and engineer with experience in synthetic biology, metabolic modeling and engineering, and high-throughput screening. At ArkeaBio, she is leveraging her passion for high-throughput methodologies to develop antigen screening and validation technologies. Kristin holds a degree in chemical engineering from Penn State and a PhD in chemical engineering from Princeton University.

Kristin Adolfsen

Lauren Fitch is a computational biologist with a passion for microbiology and synthetic biology. She has focused her career on the design and learn steps of the synthetic biology design-build-test-learn cycle, by building computational tools to design, analyze, and learn from genetically engineered microbes. At ArkeaBio, Lauren leads the antigen selection and design processes, as well as the development of next-generation sequencing pipelines to analyze data from ArkeaBio’s vaccine program. Lauren earned a BS in biology from Boston University and a PhD in molecular microbiology from Northeastern University.

Lauren Fitch

Jim Spoonamore has experience with many aspects of biotechnologies including biosensor engineering, enzymology, assay development, high throughput screening, and early stage drug discovery. He holds a PhD in biochemistry and molecular biophysics from the University of Arizona.


Tom Overbay is a business development and technical consultant bringing nearly 35 years of experience to the international animal health industry. He founded Expedite Animal Health, a global company formed to discern opportunities in animal health then assist with product development across pharmaceuticals, biologicals, devices, and diagnostics. Tom holds his veterinary degree from the Virginia-Maryland Regional College of Veterinary Medicine and resides in Louisburg, Kansas.


PR Newswire

Breakthrough Energy Ventures leads $12 million seed investment in ArkeaBio to develop and commercialize technology reducing on-farm methane emissions

Boston Real Estate Times

Freudenheim Partners relocates and expands ArkeaBio at 500 Rutherford Ave in Charlestown

Fast Company

Can a vaccine for cows slash methane emissions?

in the news

press and news articles about ArkeaBio

contact us

Contact Us